Related Experiment Videos
Clinical and pathophysiological aspects of chronic active hepatitis
1Third Department of Internal Medicine, School of Medicine, Tokai University, Japan.
The Tokai Journal of Experimental and Clinical Medicine
|January 1, 1986
Summary
The clinical significance of Hepatitis B e-antigen (HBeAg) in Hepatitis B viral hepatitis requires review. Further research is needed to fully understand the roles of HBeAg and anti-HBe in disease progression and prognosis.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B e-antigen (HBeAg) is considered a marker of infectiousness and disease progression in Hepatitis B virus (HBV) infection.
- Current understanding of HBeAg's clinical and pathological significance in HBV carriers needs re-evaluation.
Purpose of the Study:
- To critically review the clinical and pathological significance of HBeAg in Hepatitis B viral hepatitis.
- To investigate the natural history of HBeAg and anti-HBe.
- To examine the clinical course related to HBeAg to anti-HBe seroconversion.
- To explore the correlation between HBV prognosis and the persistence of HBeAg and anti-HBe.
Main Methods:
- Observational analysis of HBsAg carriers.
- Review of clinical and pathological data related to HBeAg and anti-HBe.
- Focus on seroconversion events and marker persistence.
Main Results:
- Current observations provide only a partial understanding of the natural history of HBeAg and anti-HBe.
- The full clinical and pathophysiological significance of HBeAg and anti-HBe remains largely unexplained.
Conclusions:
- The established role of HBeAg as solely an infectious and progressive factor in Hepatitis B viral hepatitis warrants careful reconsideration.
- Further comprehensive studies are essential to elucidate the complete roles and implications of HBeAg and anti-HBe in HBV infection.